Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: Epitope definition and implications in risk stratification of patients under natalizumab therapy

Antiviral Research

Volumn 108, Issue 1, 2014, Pages 94-103

  Diotti, Roberta Antonia ^a   Mancini, Nicasio ^a   Clementi, Nicola ^a   Sautto, Giuseppe ^a   Moreno, Guisella Janett ^a   Criscuolo, Elena ^a   Cappelletti, Francesca ^a   Man, Petr ^b,c   Forest, Eric ^d   Remy, Louise ^d   Giannecchini, Simone ^e   Clementi, Massimo ^a   Burioni, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b INSTITUTE OF MATHEMATICS   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d CEA GRENOBLE   (France)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

JCPyV; Monoclonal antibody; Multiple sclerosis; Natalizumab; Neutralizing activity; Progressive multifocal leukoencephalopathy (PML)

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY GRE1; IMMUNOMODULATING AGENT; NATALIZUMAB; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; CAPSID PROTEIN; EPITOPE; MONOCLONAL ANTIBODY; VIRUS ANTIBODY; VP1 PROTEIN, POLYOMAVIRUS;

ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CONTROLLED STUDY; COS 7 CELL LINE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HEAVY CHAIN; HUMAN; HUMAN CLONING; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; IMMUNOPROPHYLAXIS; JC VIRUS; LIGHT CHAIN; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHAGE DISPLAY; PILOT STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SEQUENCE HOMOLOGY; SOMATIC MUTATION; STRATIFICATION; VIRUS NEUTRALIZATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MOLECULAR CLONING; POLYOMA VIRUS; PROCEDURES; SERODIAGNOSIS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CLONING, MOLECULAR; EPITOPES; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS; POLYOMAVIRUS;

EID: 84903170770     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.05.017     Document Type: Article

References (71)

1. A.J. Aksamit Jr. Progressive multifocal leukoencephalopathy Continuum (Minneap Minn) 18 2012 1374 1391
2. N. Aoki, M. Mori, K. Kato, Y. Sakamoto, K. Noda, M. Tajima, and H. Shimada Antibody against synthetic multiple antigen peptides (MAP) of JC virus capsid protein (VP1) without cross reaction to BK virus: a diagnostic tool for progressive multifocal leukoencephalopathy Neurosci. Lett. 205 1996 111 114 (Pubitemid 26071325)
3. K.E. Astrom, E.L. Mancall, and E.P. Richardson Jr. Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease Brain 81 1958 93 111
4. W.J. Atwood A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukoencephalopathy J. Neurovirol. 7 2001 307 310 (Pubitemid 32894233)
5. A. Bellizzi, C. Nardis, E. Anzivino, D. Rodio, D. Fioriti, M. Mischitelli, F. Chiarini, and V. Pietropaolo Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies J. Neurovirol. 18 2012 1 11
6. G. Bloomgren, S. Richman, C. Hotermans, M. Subramanyam, S. Goelz, A. Natarajan, S. Lee, T. Plavina, J.V. Scanlon, A. Sandrock, and C. Bozic Risk of natalizumab-associated progressive multifocal leukoencephalopathy N. Engl. J. Med. 366 2012 1870 1880
7. S. Bofill-Mas, P. Clemente-Casares, E.O. Major, B. Curfman, and R. Girones Analysis of the excreted JC virus strains and their potential oral transmission J. Neurovirol. 9 2003 498 507 (Pubitemid 36986816)
8. B. Bollag, C. Prins, E.L. Snyder, and R.J. Frisque Purified JC virus T and T′ proteins differentially interact with the retinoblastoma family of tumor suppressor proteins Virology 274 2000 165 178 (Pubitemid 30650691)
9. C. Bozic, S. Richman, T. Plavina, A. Natarajan, J.V. Scanlon, M. Subramanyam, A. Sandrock, and G. Bloomgren Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1 Ann. Neurol. 70 2011 742 750
10. B.R. Brooks, and D.L. Walker Progressive multifocal leukoencephalopathy Neurol. Clin. 2 1984 299 313
11. F. Bugli, N. Mancini, C.Y. Kang, C. Di Campli, A. Grieco, A. Manzin, A. Gabrielli, A. Gasbarrini, G. Fadda, P.E. Varaldo, M. Clementi, and R. Burioni Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries J. Virol. 75 2001 9986 9990 (Pubitemid 32900134)
12. R. Burioni, P. Plaisant, F. Bugli, V. Delli Carri, M. Clementi, and G. Fadda A vector for the expression of recombinant monoclonal Fab fragments in bacteria J. Immunol. Methods 217 1998 195 199 (Pubitemid 28449043)
13. R. Burioni, Y. Matsuura, N. Mancini, H. Tani, T. Miyamura, P.E. Varaldo, and M. Clementi Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype J. Virol. 76 2002 11775 11779 (Pubitemid 35231335)
14. R. Burioni, N. Mancini, D. De Marco, N. Clementi, M. Perotti, G. Nitti, M. Sassi, F. Canducci, K. Shvela, P. Bagnarelli, J.R. Mascola, and M. Clementi Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site PLoS One 3 2008 e3423
15. R. Burioni, M. Perotti, N. Mancini, and M. Clementi Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs J. Hepatol. 49 2008 299 300
16. R. Burioni, F. Canducci, N. Mancini, N. Clementi, M. Sassi, D. De Marco, D. Saita, R.A. Diotti, G. Sautto, M. Sampaolo, and M. Clementi Molecular cloning of the first human monoclonal antibodies neutralizing with high potency swine-origin influenza A pandemic virus (S-OIV) New Microbiol. 32 2009 319 324
17. R. Burioni, F. Canducci, D. Saita, M. Perotti, N. Mancini, D. De Marco, N. Clementi, A. Chieffo, M. Denaro, D. Cianflone, A.A. Manfredi, A. Colombo, A. Maseri, and M. Clementi Antigen-driven evolution of B lymphocytes in coronary atherosclerotic plaques J. Immunol. 183 2009 2537 2544
18. R. Burioni, F. Canducci, N. Mancini, N. Clementi, M. Sassi, D. De Marco, R.A. Diotti, D. Saita, M. Sampaolo, G. Sautto, M. Pianezze, and M. Clementi Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin influenza virus (S-OIV) Virology 399 2010 144 152
19. G.Y. Chuang, P. Acharya, S.D. Schmidt, Y. Yang, M.K. Louder, T. Zhou, Y.D. Kwon, M. Pancera, R.T. Bailer, N.A. Doria-Rose, M.C. Nussenzweig, J.R. Mascola, P.D. Kwong, and I.S. Georgiev Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains J. Virol. 87 2013 10047 10058
20. P. Cinque, I.J. Koralnik, S. Gerevini, J.M. Miro, and R.W. Price Progressive multifocal leukoencephalopathy in HIV-1 infection Lancet Infect. Dis 9 2009 625 636
21. N. Clementi, D. De Marco, N. Mancini, L. Solforosi, G.J. Moreno, L.V. Gubareva, V. Mishin, A. Di Pietro, E. Vicenzi, A.G. Siccardi, M. Clementi, and R. Burioni A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes PLoS One 6 2011 e28001
22. N. Clementi, N. Mancini, L. Solforosi, M. Castelli, M. Clementi, and R. Burioni Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens Int. J. Mol. Sci. 13 2012 8273 8292
23. D. De Marco, N. Clementi, N. Mancini, L. Solforosi, G.J. Moreno, X. Sun, T.M. Tumpey, L.V. Gubareva, V. Mishin, M. Clementi, and R. Burioni A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses PLoS One 7 2012 e34415
24. S. Delbue, E. Branchetti, S. Bertolacci, E. Tavazzi, E. Marchioni, R. Maserati, G. Minnucci, S. Tremolada, G. Vago, and P. Ferrante JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathy J. Neurovirol. 15 2009 51 56
25. R.A. Diotti, G.A. Sautto, L. Solforosi, N. Mancini, M. Clementi, and R. Burioni Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C virus E2 glycoprotein New Microbiol. 35 2012 475 479
26. S. Eash, K. Manley, M. Gasparovic, W. Querbes, and W.J. Atwood The human polyomaviruses Cell. Mol. Life Sci. 63 2006 865 876 (Pubitemid 43731778)
27. A. Egli, L. Infanti, A. Dumoulin, A. Buser, J. Samaridis, C. Stebler, R. Gosert, and H.H. Hirsch Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors J. Infect. Dis. 199 2009 837 846
28. M.W. Ferenczy, L.J. Marshall, C.D. Nelson, W.J. Atwood, A. Nath, K. Khalili, and E.O. Major Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain Clin. Microbiol. Rev. 25 2012 471 506
29. R.J. Frisque, J.D. Martin, B.L. Padgett, and D.L. Walker Infectivity of the DNA from four isolates of JC virus J. Virol. 32 1979 476 482 (Pubitemid 10188762)
30. S. Frye, C. Trebst, U. Dittmer, H. Petry, M. Bodemer, G. Hunsmann, T. Weber, and W. Luke Efficient production of JC virus in SVG cells and the use of purified viral antigens for analysis of specific humoral and cellular immune response J. Virol. Methods 63 1997 81 92 (Pubitemid 27064458)
31. G.V. Gee, N. Tsomaia, D.F. Mierke, and W.J. Atwood Modeling a sialic acid binding pocket in the external loops of JC virus VP1 J. Biol. Chem. 279 2004 49172 49176 (Pubitemid 39625800)
32. L. Gorelik, M. Lerner, S. Bixler, M. Crossman, B. Schlain, K. Simon, A. Pace, A. Cheung, L.L. Chen, M. Berman, F. Zein, E. Wilson, T. Yednock, A. Sandrock, S.E. Goelz, and M. Subramanyam Anti-JC virus antibodies: implications for PML risk stratification Ann. Neurol. 68 2010 295 303
33. L. Gorelik, C. Reid, M. Testa, M. Brickelmaier, S. Bossolasco, A. Pazzi, A. Bestetti, P. Carmillo, E. Wilson, M. McAuliffe, C. Tonkin, J.P. Carulli, A. Lugovskoy, A. Lazzarin, S. Sunyaev, K. Simon, and P. Cinque Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity J. Infect. Dis. 204 2011 103 114
34. R. Gosert, C.H. Rinaldo, M. Wernli, E.O. Major, and H.H. Hirsch CMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytes Antimicrob. Agents Chemother. 55 2011 2129 2136
35. K. Hara, C. Sugimoto, T. Kitamura, N. Aoki, F. Taguchi, and Y. Yogo Archetype JC virus efficiently replicates in COS-7 cells, simian cells constitutively expressing simian virus 40 T antigen J. Virol. 72 1998 5335 5342 (Pubitemid 28283312)
36. A. Hiatt, L. Zeitlin, and K.J. Whaley Multiantibody strategies for HIV Clin. Dev. Immunol. 2013 2013 632893
37. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J. Mol. Graph. 14 1 1996 33 38 (27-8) (Pubitemid 26152973)
38. J.P. Julien, J.H. Lee, A. Cupo, C.D. Murin, R. Derking, S. Hoffenberg, M.J. Caulfield, C.R. King, A.J. Marozsan, P.J. Klasse, R.W. Sanders, J.P. Moore, I.A. Wilson, and A.B. Ward Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9 Proc. Natl. Acad. Sci. U.S.A. 110 2013 4351 4356
39. W.A. Knowles, P. Pipkin, N. Andrews, A. Vyse, P. Minor, D.W. Brown, and E. Miller Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40 J. Med. Virol. 71 2003 115 123 (Pubitemid 37121921)
40. I.J. Koralnik Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy J. Neurovirol. 8 Suppl. 2 2002 59 65 (Pubitemid 36097778)
41. J. Lin, P. Bettin, J.K. Lee, J.K. Ho, and S.A. Sadiq Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab J. Neuroimmunol. 261 2013 123 128
42. T. Mahmood, and P.C. Yang Western blot: technique, theory, and trouble shooting North Am. J. Med. Sci. 4 2012 429 434
43. E.O. Major Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies Annu. Rev. Med. 61 2010 35 47
44. E.O. Major, D.A. Vacante, R.G. Traub, W.T. London, and J.L. Sever Owl monkey astrocytoma cells in culture spontaneously produce infectious JC virus which demonstrates altered biological properties J. Virol. 61 1987 1435 1441 (Pubitemid 17069731)
45. N. Mancini, M. Perotti, S. Carletti, F. Canducci, M. Sampaolo, M. Clementi, and R. Burioni Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient Mol. Immunol. 43 2006 1363 1369 (Pubitemid 43361593)
46. N. Mancini, R.A. Diotti, M. Perotti, G. Sautto, N. Clementi, G. Nitti, A.H. Patel, J.K. Ball, M. Clementi, and R. Burioni Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes PLoS One 4 2009 e8254
47. N. Mancini, M. Clementi, and R. Burioni Natalizumab-associated progressive multifocal leukoencephalopathy N. Engl. J. Med. 367 2012 871 872 (author reply 872)
48. N. Mancini, G. Sautto, N. Clementi, R.A. Diotti, E. Criscuolo, M. Castelli, L. Solforosi, M. Clementi, and R. Burioni Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape? Viruses 4 2012 1731 1752
49. S.J. Marriott, and R.A. Consigli Production and characterization of monoclonal antibodies to polyomavirus major capsid protein VP1 J. Virol. 56 1985 365 372 (Pubitemid 16192320)
50. A. Nakanishi, B. Chapellier, N. Maekawa, M. Hiramoto, T. Kuge, R.U. Takahashi, H. Handa, and T. Imai SV40 vectors carrying minimal sequence of viral origin with exchangeable capsids Virology 379 2008 110 117
51. C.D. Nelson, A. Derdowski, M.S. Maginnis, B.A. O'Hara, and W.J. Atwood The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry Virology 428 2012 30 40
52. U. Neu, M.S. Maginnis, A.S. Palma, L.J. Stroh, C.D. Nelson, T. Feizi, W.J. Atwood, and T. Stehle Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif Cell Host Microbe 8 2010 309 319
53. M.R. Perkins, C. Ryschkewitsch, J.C. Liebner, M.C. Monaco, D. Himelfarb, S. Ireland, A. Roque, H.L. Edward, P.N. Jensen, G. Remington, T. Abraham, J. Abraham, B. Greenberg, C. Kaufman, C. LaGanke, N.L. Monson, X. Xu, E. Frohman, E.O. Major, and D.C. Douek Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy PLoS Pathog. 8 2012 e1003014
54. M. Perotti, N. Mancini, R.A. Diotti, A.W. Tarr, J.K. Ball, A. Owsianka, R. Adair, A.H. Patel, M. Clementi, and R. Burioni Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein J. Virol. 82 2008 1047 1052
55. P. Randhawa, R. Viscidi, J.J. Carter, D.A. Galloway, T.D. Culp, C. Huang, B. Ramaswami, and N.D. Christensen Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies J. Gen. Virol. 90 2009 634 639
56. E.P. Rock, P.R. Sibbald, M.M. Davis, and Y.H. Chien CDR3 length in antigen-specific immune receptors J. Exp. Med. 179 1994 323 328 (Pubitemid 24012999)
57. G. Sautto, N. Mancini, M. Clementi, and R. Burioni Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII) Viruses 4 2012 2924 2944
58. L. Solforosi, N. Mancini, F. Canducci, N. Clementi, G.A. Sautto, R.A. Diotti, M. Clementi, and R. Burioni A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments New Microbiol. 35 2012 289 294
59. I. Steiner, and J.R. Berger Update on progressive multifocal leukoencephalopathy Curr. Neurol. Neurosci. Rep. 12 2012 680 686
60. C. Sugimoto, M. Hasegawa, A. Kato, H.Y. Zheng, H. Ebihara, F. Taguchi, T. Kitamura, and Y. Yogo Evolution of human polyomavirus JC: implications for the population history of humans J. Mol. Evol. 54 2002 285 297 (Pubitemid 34165414)
61. S.R. Sunyaev, A. Lugovskoy, K. Simon, and L. Gorelik Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML) PLoS Genet. 5 2009 e1000368
62. C.S. Tan, Y. Chen, R.P. Viscidi, R.P. Kinkel, M.C. Stein, and I.J. Koralnik Discrepant findings in immune responses to JC virus in patients receiving natalizumab Lancet Neurol. 9 2010 565 566 (author reply 566-567)
63. E. Tavazzi, M.K. White, and K. Khalili Progressive multifocal leukoencephalopathy: clinical and molecular aspects Rev. Med. Virol. 22 2012 18 32
64. P. Vermersch, L. Kappos, R. Gold, J.F. Foley, T. Olsson, D. Cadavid, C. Bozic, and S. Richman Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy Neurology 76 2011 1697 1704
65. M. Wang, T.Y. Tzeng, C.Y. Fung, W.C. Ou, R.T. Tsai, C.K. Lin, G.J. Tsay, and D. Chang Human anti-JC virus serum reacts with native but not denatured JC virus major capsid protein VP1 J. Virol. Methods 78 1999 171 176 (Pubitemid 29117286)
66. F. Weber, C. Goldmann, M. Kramer, F.J. Kaup, M. Pickhardt, P. Young, H. Petry, T. Weber, and W. Luke Cellular and humoral immune response in progressive multifocal leukoencephalopathy Ann. Neurol. 49 2001 636 642 (Pubitemid 32429790)
67. O. Yaldizli, and N. Putzki Natalizumab in the treatment of multiple sclerosis Ther. Adv. Neurol. Dis. 2 2009 115 128
68. M. Yamada, R. Wasserman, B.A. Reichard, S. Shane, A.J. Caton, and G. Rovera Preferential utilization of specific immunoglobulin heavy chain diversity and joining segments in adult human peripheral blood B lymphocytes J. Exp. Med. 173 1991 395 407
69. T.A. Yednock, C. Cannon, L.C. Fritz, F. Sanchez-Madrid, L. Steinman, and N. Karin Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin Nature 356 1992 63 66
70. Q. Zhang, L.N. Willison, P. Tripathi, S.K. Sathe, K.H. Roux, M.R. Emmett, G.T. Blakney, H.M. Zhang, and A.G. Marshall Epitope mapping of a 95 kDa antigen in complex with antibody by solution-phase amide backbone hydrogen/deuterium exchange monitored by Fourier transform ion cyclotron resonance mass spectrometry Anal. Chem. 83 2011 7129 7136
71. H.Y. Zheng, H. Ikegaya, T. Takasaka, T. Matsushima-Ohno, M. Sakurai, I. Kanazawa, S. Kishida, K. Nagashima, T. Kitamura, and Y. Yogo Characterization of the VP1 loop mutations widespread among JC polyomavirus isolates associated with progressive multifocal leukoencephalopathy Biochem. Biophys. Res. Commun. 333 2005 996 1002 (Pubitemid 40854255)